Get the Stockscreener App
12.13
0.13%
0.10
Maze Therapeutics Inc stock is traded at $12.13, with a volume of 28,859.
It is up +0.13% in the last 24 hours and down -18.36% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$12.23
Open:
$12.17
24h Volume:
28,859
Relative Volume:
0.31
Market Cap:
$531.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+13.18%
1M Performance:
-18.36%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$11.54
$12.58
1-Week Range:
$10.08
$13.24
52-Week Range:
$10.08
$16.09
Maze Therapeutics Inc Stock (MAZE) Company Profile
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
12.13 | 531.01M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.49 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.34 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.79 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Maze Therapeutics Inc Stock (MAZE) Latest News
Leerink Partners Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.6%Still a Buy? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Guggenheim Begins Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Upgraded at TD Cowen - Defense World
FY2024 Earnings Forecast for MAZE Issued By Leerink Partnrs - Defense World
FY2024 Earnings Estimate for MAZE Issued By Leerink Partnrs - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at JPMorgan Chase & Co. - Defense World
Maze Therapeutics (NASDAQ:MAZE) Coverage Initiated at Guggenheim - Defense World
Maze Therapeutics (NASDAQ:MAZE) Raised to “Strong-Buy” at Leerink Partnrs - Defense World
Maze Therapeutics initiated with a Buy at TD Cowen - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Now Covered by Analysts at Leerink Partners - Defense World
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829 - TipRanks
Cowen initiates Maze Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Maze Therapeutics receives positive ratings following recent IPO - Investing.com
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Guggenheim sets $19 target on Maze Therapeutics stock By Investing.com - Investing.com Canada
Guggenheim Initiates Maze Therapeutics at Buy With $19 Price Target -February 25, 2025 at 06:43 am EST - Marketscreener.com
JPMorgan Initiates Maze Therapeutics at Overweight With $30 Price Target -February 25, 2025 at 06:32 am EST - Marketscreener.com
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics - TipRanks
Maze Therapeutics initiated with an Outperform at Leerink - TipRanks
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market - TipRanks
JPMorgan sets Maze Therapeutics stock to Overweight with $30 target By Investing.com - Investing.com Canada
This New Drug Mimics The Health Effects of Living at High Altitude - ScienceAlert
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month LowShould You Sell? - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Hits New 12-Month Low – Here’s Why - Armenian Reporter
Maze Therapeutics (NASDAQ:MAZE) Shares Down 3.9%Here's Why - MarketBeat
Maze Therapeutics begins Phase 2 trial for kidney disease drug - MSN
Tesla, ON Semiconductor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Maze Therapeutics doses first subject in Phase II AKD treatment trial - Yahoo Finance
Maze Therapeutics’ $140 Million Upsized Initial Public Offering - Global Legal Chronicle
Cyclo Therapeutics reports promising NPC1 treatment findings - MSN
Maze Therapeutics begins Phase 2 trial for kidney disease drug By Investing.com - Investing.com Australia
Maze Therapeutics Doses First Patient in Phase 2 HORIZON - GlobeNewswire
Groundbreaking Kidney Disease Trial: Maze's APOL1 Inhibitor Targets 1M+ Patient Market - StockTitan
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Metsera, Maze land on NASDAQ as IPO queue grows - BioCentury
Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN
Maze Therapeutics valued at $690.4 million in lukewarm Nasdaq debut - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Maze Therapeutics IPO opens trading modestly higher - MSN
Maze Therapeutics valued at $690.4 million as shares rise marginally in market debut - MSN
Maze Therapeutics IPO opens trading modestly higher By Investing.com - Investing.com Canada
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Maze Therapeutics Opens At $16.12, IPO Priced At $16 By Investing.com - Investing.com Canada
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
FiDi-based obesity drug maker sees $1.9B IPO - Crain's New York Business
MAZE IPO NewsPrecision medicine biotech Maze Therapeutics prices upsized IPO at the $16 midpoint - Renaissance Capital
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):